The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms ...